立体定向放射外科治疗脑转移瘤:单中心11年经验的多状态与竞争风险模型分析
该回顾性队列研究纳入2010至2020年在Leeds Gamma Knife中心接受SRS治疗的1031例患者(2836个转移灶),随访至少30个月。肺癌、乳腺癌和黑色素瘤是最常见原发肿瘤,随访期间35.3%患者复发、84.5%死亡。每增加一个转移灶进展风险增加9.2%,每增加1cm³总肿瘤体积死亡风险增加2.2%,SRS后新发转移使死亡风险增加31%。
要点
- 每增加一个转移灶进展风险增加9.2%,但病灶数量不影响死亡风险。
- 总肿瘤体积每增加1cm³死亡风险增加2.2%。
- SRS后新发转移使死亡风险增加31%,局部复发未显著影响死亡。
核心结论
- SRS治疗脑转移瘤的预后受病灶数量、总肿瘤体积及SRS后新发转移影响,这些因素可辅助临床咨询。
研究设计与样本
- 回顾性队列研究纳入2010至2020年Leeds Gamma Knife中心接受SRS的1031例患者(2836个转移灶),随访至少30个月。
主要发现
- 肺癌(50.4%)、乳腺癌(15.4%)和黑色素瘤(9.9%)是最常见原发肿瘤。
- 364例(35.3%)患者出现复发,875例(84.5%)在随访结束时死亡。
- 男性肺癌(p=0.003)和其他转移(p=0.02)患者生存结局较女性差。
- 乳腺癌患者无进展状态时间最长(rmean=1.56年),胃肠道原发肿瘤最短(rmean=0.99年)。
- 每增加一个转移灶进展风险增加9.2%(p<0.001),但病灶数量与死亡风险无关(p=0.30)。
关键数值与推荐
- 总肿瘤体积每增加1cm³死亡风险增加2.2%。
- SRS后新发转移使死亡风险增加31%(p=0.02),局部复发未显著影响死亡(p=0.26)。
临床怎么用
- 咨询时可结合转移灶数量、总肿瘤体积及SRS后新发转移风险向患者说明预后。
局限性
- 单中心回顾性设计,结论外推需谨慎,SRS与其他治疗的关系尚待进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The diagnosis of brain metastases has risen due to advances in systemic treatments prolonging survival and the use of MRI. Whilst surgical resection remains a valuable mean of acutely alleviating raised intracranial pressure, reducing seizure risk, and preventing progression of neurological deficit, stereotactic radiosurgery (SRS) delivers radiotherapy to precise target volumes, including the treatment of a larger number of metastases with high rates of local control, whilst avoiding the neurological complications of WBRT or the need for invasive resection. The aim of this study was to evaluate the 11-year experience of SRS at the Leeds Gamma Knife Centre, examining patient outcomes, and the association of patient-dependent factors and intracranial disease burden to survival. METHODS: A retrospective cohort study of 1,031 patients (2,836 metastases) treated with SRS at the Leeds Gamma Knife Centre between 2010 and 2020. Data included primary tumour, Karnofsky performance status, intracranial disease burden, and prior/subsequent treatment. Follow-up was at least 30 months. Kaplan-Meier analysis was used for 10-year survival curves. Multistate and competing risks models assessed progression/death predictors. RESULTS: Lung (50.4%), breast (15.4%) and melanoma (9.9%) were the most common primary tumour. 364 (35.3%) patients had recurrence, and 875 (84.5%) died by the end of follow-up. Survival outcomes were worse in men compared to women in both lung (p = 0.003) and other (p = 0.02) metastases. Breast cancer patients spent the most time in the no progression state (rmean = 1.56 years) whereas gastrointestinal primary spent the least (rmean = 0.99 years). Each additional metastatic lesion at the time of treatment increased the risk of progression by 9.2% (p < 0.001), but risk of death was not influenced by the number of lesions (p = 0.30); conversely, total tumour volume increased the risk of death by 2.2% for each 1cm3 increase. Post-SRS new metastatic disease increased the risk of death by 31% (p = 0.02), whilst local recurrence did not (p = 0.26). CONCLUSION: These findings add to the accepted prognostic factors for brain metastases, further informing clinical consultations with patients, but further research is required to address unanswered questions regarding the role of SRS in relation to other treatments.
引用
- Reveendran D, Crispi V, Fairclough S, et al. Stereotactic radiosurgery for brain metastases: multistate and competing risk models of progression and survival from a single-centre 11-year experience. Radiat Oncol. 2026. PMID: 41645238. doi:10.1186/s13014-025-02779-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。